Daewoong pharmaceutical Co.,Ltd

069620.KS

069620.KSDaewoong pharmaceutical Co.,Ltd KR flag

KSE

130,000.00

KRW

+400.00

(+0.31%)

1.50TMarket Cap

Apr 28Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7069620003

Return %

Stock

S&P500

18.07

6.57

-23.30

22.75

19.82

93.55

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	64,821.87	66,124.3	71,292.3	81,367.13	85,639.58	93,048.97	99,930.74	107,872.04	98,976.29	104,778.6	115,645.98	106,959.52	- -	123,608.95
Basic EPS, GAAP	3,302	5,658	3,056	4,160	2,613	3,060	-1,468	2,132	1,196	2,227	3,816	9,759.95	- -	2,149.04
Free Cash Flow per Basic Share	1,273.81	3,397.13	-2,229.27	-6,048.69	-14,326.98	695.97	-926.43	725.99	3,871.65	-3,162.51	443.2	1,216.14	- -	-15,422.9
Dividend per Share	754.08	776.64	799.9	700.08	699.96	600.02	599.97	599.95	580.73	586.85	728.67	581.34	- -	39.52
Book Value per Share	31,202.54	36,044.96	37,467.06	41,259.51	43,171.28	45,635.63	42,702.68	44,824.27	45,179.59	45,104.56	48,175.81	59,241.64	- -	57,746.91
Tangible Book Value per Share	34,577.9	39,742.26	41,086.07	42,977.72	43,942.7	44,335.46	44,396.58	45,654.59	48,437.34	42,961.63	42,931.87	52,195.92	- -	50,416.82
Basic Weighted Avg Shares	10	10	10	10	10	10	10	10	11	11	11	11	- -	12
Sales/Revenue/Turnover	669,014	682,508	735,889	839,686	883,920	960,307	1,031,427	1,113,426	1,055,424	1,152,976	1,280,092	1,221,951	1,422,683	1,422,683
Operating Margin (%)	5.51	10.46	7.06	5.19	2.93	4.06	2.68	4.01	1.61	7.7	7.48	10.92	10.4	10.4
Depreciation Expense	17,954	18,177	17,573	23,099	27,814	40,115	51,300	40,195	40,882	40,883	39,695	35,661	48,978	48,978
Net Income, GAAP	34,079	58,400	31,544	42,930	26,970	31,581	-15,152	22,006	12,753	24,506	42,240	111,502	24,735	24,735
Effective Tax Rate (%)	19.68	21.66	43.24	25.29	5.37	1.93	- -	- -	- -	- -	- -	0.12	58.72	58.72
Profit Margin (%)	5.09	8.56	4.29	5.11	3.05	3.29	-1.47	1.98	1.21	2.13	3.3	9.12	1.74	1.74
Working Capital	151,924	224,923	324,107	303,668	284,626	250,083	148,265	264,176	201,601	59,742	76,137	-303,185	-16,623	-16,623
LT Debt	- -	39,866	139,512	189,410	289,165	289,336	179,486	292,601	297,728	188,721	211,855	66,322	325,752	325,752
Total Equity	386,587	437,963	455,506	580,241	604,551	631,537	607,809	635,920	695,249	697,915	741,223	802,975	926,985	926,985
Return on Invested Capital (%)	7.41	12.5	5.38	4.58	2.69	3.79	- -	- -	- -	- -	- -	11.09	4.38	7.85
Return on Capital (%)	10.62	15.87	6.96	8.07	3.77	3.74	- -	- -	- -	- -	- -	11.19	2.27	3.99
Return on Common Equity (%)	10.96	16.83	8.31	10.57	6.19	6.89	-3.32	4.87	2.7	5.01	8.21	18.43	3.69	7.44

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.03%	5.39%	16.43%
Net Income, GAAP	-16.86%	41.73%	-77.82%
Free Cash Flow	-125.01%	-208.37%	-1,377.63%
Total Cash Common Dividend	- -	- -	16.55%
Total Equity	7.66%	7.94%	15.44%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Chang-Jae Lee
Full Time Employees: 1,727
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 12, Bongeunsa-ro 114-gil Seoul South Korea 135-715
IPO Date: Sep 29, 2005
Website: daewoong.com
Similar Companies: Gelteq Limited Ordinary Shares (GELS)
Sativa Growth International (SAGD)
Elixxer Ltd. (ELIXF)
Xiamen Kingdomway Group Company (002626.SZ)
Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
BioGaia AB (publ) (BIOGY)
Business: Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	64,821.87	66,124.3	71,292.3	81,367.13	85,639.58	93,048.97	99,930.74	107,872.04	98,976.29	104,778.6	115,645.98	106,959.52	- -	123,608.95
Basic EPS, GAAP	3,302	5,658	3,056	4,160	2,613	3,060	-1,468	2,132	1,196	2,227	3,816	9,759.95	- -	2,149.04
Free Cash Flow per Basic Share	1,273.81	3,397.13	-2,229.27	-6,048.69	-14,326.98	695.97	-926.43	725.99	3,871.65	-3,162.51	443.2	1,216.14	- -	-15,422.9
Dividend per Share	754.08	776.64	799.9	700.08	699.96	600.02	599.97	599.95	580.73	586.85	728.67	581.34	- -	39.52
Book Value per Share	31,202.54	36,044.96	37,467.06	41,259.51	43,171.28	45,635.63	42,702.68	44,824.27	45,179.59	45,104.56	48,175.81	59,241.64	- -	57,746.91
Tangible Book Value per Share	34,577.9	39,742.26	41,086.07	42,977.72	43,942.7	44,335.46	44,396.58	45,654.59	48,437.34	42,961.63	42,931.87	52,195.92	- -	50,416.82
Basic Weighted Avg Shares	10	10	10	10	10	10	10	10	11	11	11	11	- -	12
Sales/Revenue/Turnover	669,014	682,508	735,889	839,686	883,920	960,307	1,031,427	1,113,426	1,055,424	1,152,976	1,280,092	1,221,951	1,422,683	1,422,683
Operating Margin (%)	5.51	10.46	7.06	5.19	2.93	4.06	2.68	4.01	1.61	7.7	7.48	10.92	10.4	10.4
Depreciation Expense	17,954	18,177	17,573	23,099	27,814	40,115	51,300	40,195	40,882	40,883	39,695	35,661	48,978	48,978
Net Income, GAAP	34,079	58,400	31,544	42,930	26,970	31,581	-15,152	22,006	12,753	24,506	42,240	111,502	24,735	24,735
Effective Tax Rate (%)	19.68	21.66	43.24	25.29	5.37	1.93	- -	- -	- -	- -	- -	0.12	58.72	58.72
Profit Margin (%)	5.09	8.56	4.29	5.11	3.05	3.29	-1.47	1.98	1.21	2.13	3.3	9.12	1.74	1.74
Working Capital	151,924	224,923	324,107	303,668	284,626	250,083	148,265	264,176	201,601	59,742	76,137	-303,185	-16,623	-16,623
LT Debt	- -	39,866	139,512	189,410	289,165	289,336	179,486	292,601	297,728	188,721	211,855	66,322	325,752	325,752
Total Equity	386,587	437,963	455,506	580,241	604,551	631,537	607,809	635,920	695,249	697,915	741,223	802,975	926,985	926,985
Return on Invested Capital (%)	7.41	12.5	5.38	4.58	2.69	3.79	- -	- -	- -	- -	- -	11.09	4.38	7.85
Return on Capital (%)	10.62	15.87	6.96	8.07	3.77	3.74	- -	- -	- -	- -	- -	11.19	2.27	3.99
Return on Common Equity (%)	10.96	16.83	8.31	10.57	6.19	6.89	-3.32	4.87	2.7	5.01	8.21	18.43	3.69	7.44

	Jun'24	Sep'24	Dec'24
ST Debt	291,394	251,095	323,497
LT Borrowings	259,255	337,340	324,478
LT Finance Leases	1,326	1,300	1,274
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	12	12	12
Market Capitalization	1,172,868	1,584,037	1,454,807

Year	Q1	Q2	Q3	Q4	FY
2022	1,230	1,578	1,852	- -	3,816
2023	1,379	2,150	1,354	- -	9,759.95
2024	708	99	2,458	- -	- -

	Jun'24	Sep'24	Dec'24
Total Current Assets	589,613	574,231	612,792
Accounts Receivable, Net	165,477	146,553	160,742
Cash, Cash Equivalents & STI	110,314	107,511	116,347
Inventories	246,462	246,192	256,353
Total Current Liabilities	616,890	538,132	629,416
Payables & Accruals	- -	- -	- -
ST Debt	291,394	251,095	323,497
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	298,356	322,059	331,893	327,784	1,280,092
2023	322,415	350,191	340,900	- -	1,221,951
2024	335,785	360,545	358,473	367,880	1,422,683

Year	Q1	Q2	Q3	Q4	FY
2022	50.7	600.76	0.91	- -	728.67
2023	- -	- -	55.56	- -	581.34
2024	- -	- -	38.86	- -	- -

Daewoong pharmaceutical Co.,Ltd

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Quarterly Earnings Per Share

Year

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year